Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and ControlsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether the gut microbiome differs between celiac disease, a genetically at-risk pre-disease state, and controls. Researchers sampled both the small intestine and stool. They used 16S rRNA gene sequencing on duodenal biopsies and faecal samples. DADA2 resolved amplicon sequence variants. Predicted metagenomes assessed the microbes' capacity to degrade gluten.
Who was studied?
The cohort was 62 adults in New Delhi, India. It included 23 treatment-naive celiac patients (all HLA-DQ2 or DQ8 positive with villous abnormalities), 15 healthy first-degree relatives, and 24 controls with hepatitis B carriage or functional dyspepsia. All participants ate a gluten-containing diet at sampling. Duodenal biopsies and stool were collected from each. Groups differed significantly in age.
What were the most important findings?
Overall diversity did not differ between celiac, relatives, and controls, but specific sequence variants did. Duodenal samples showed larger disruption than stool, indicating stronger change at the disease site. At the phylum level, Actinobacteria and Bacteroides were higher in relatives than controls, and the order Clostridiales was enriched in relatives in both gut sites. Predicted metagenomes showed celiac faecal microbiota had reduced Xaa-pro dipeptidase (prolidase), a gluten-degrading enzyme, versus relatives and controls.
What are the greatest implications of this study?
The findings suggest fine-grained bacterial variants, not broad diversity, distinguish celiac from the at-risk pre-disease state. Relatives may carry a more balanced, SCFA-producing microbiota that could be protective. Reduced predicted gluten-degrading capacity in celiac stool hints that microbes influence gluten processing. This was inferred, not measured by enzyme assay. Strain-level and functional follow-up is needed before any causal or clinical claim.